Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant

Cancer Research

Volumn 57, Issue 15, 1997, Pages 3230-3237

  Aruga, Atsushi ^a,b   Aruga, Etsuko ^a,c   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CD3 ANTIGEN; CYTOKINE; INTERLEUKIN 2; TUMOR VACCINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN 3T3; CYTOTOXICITY; FIBROBLAST; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNE FUNCTION TEST; METASTASIS; PRIORITY JOURNAL; TUMOR CELL; TUMOR CELL CULTURE; VACCINATION;

3T3 CELLS; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; FIBROBLASTS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; LYMPH NODES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; SARCOMA, EXPERIMENTAL; TRANSFECTION; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC; TUMOR CELLS, CULTURED;

EID: 0030854844     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Miller, A. R., McBride, W. H., Hunt, K., and Economou, J. S. Cytokine-mediated gene therapy for cancer. Ann. Surg. Oncol., 1: 436-450, 1994.
2. Gilboa, E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin. Oncol., 23: 101-107, 1996.
3. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama H., Baker, M., and Pardoll, D. M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (Washington DC), 254: 713-716, 1991.
4. Connor, J., Bannerji, R., Saito, S., Heston, W., Fair, W., and Gilboa E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med., 177: 1127-1134, 1993.
5. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., and Lotze, M. T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol., 154: 6466-6474, 1995.
6. Chang, A. E., Sondak., V. K., Bishop, D. K., Nickoloff, B. J., Mulligan, R. C., and Mulé, J. J. Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum. Gene Ther., 7: 773-792, 1996.
7. Shawler, D. L., Dorigo, O., Gjerset, R. A., Royston, I., Sobol, R. E., and Fakhrai, H. Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma. J. Immunother., 17: 201-208, 1995.
8. Tahara, H., Zeh, H. J., Storkus, W. J., Pappo, I., Watkins, S. C., Gubler, U., Wolf, S. F., Robbins, P. D., and Lotze, M. T. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res., 54: 182-189, 1994.
9. Tahara, H., Lotze, M. T., Robbins, P. D., Storkus, W. J., and Zitvogel, L. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum. Gene Ther., 6: 1607-1624, 1995.
10. Lotze, M. T., Rubin, J. T., Carty, S., Edington, H., Person, P., Landrencau, R., Pippin, B., Posner, M., Rosenfelder, D., Watson, C., et al. Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit and immune response. Hum. Gene Ther., 5: 41-55, 1994.
11. Area, M. J., Krauss, J. C., Aruga, A., Cameron, M. J., Shu, S., and Chang, A. E. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther., 3: 39-47, 1996.
12. Aruga, E., Aruga, A., Area, M. J., Lee, W. M. F., Yang, N-S., Smith, J. W., and Chang, A. E. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, IL-12 or GM-CSF. Cancer Gene Ther., 4: 157-166, 1997.
13. Area, M. J., Krauss, J. C., Strome, S. E., Cameron, M. J., and Chang, A. E. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol. Immunother., 42: 237-245, 1996.
14. NIH publication No. 85-23, revised 1985.
15. Hart, I. R. The selection and characterization of an invasive variant of the B16 melanoma. Am. J. Pathol., 97: 587-600, 1979.
16. Barth, R. J., Bock, S. N., Mulé, J. J., and Rosenberg, S. A. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J. Immunol., 144: 1531-1537, 1990.
17. Yoshizawa, H., Chang, A. E., and Shu, S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol., 147: 729-737, 1991.
18. Leo, O., Foo, M., Sachs, D. H., Samelson, L. E., and Bluestone, J. A. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA, 84: 1374-1378, 1987.
19. Shu, S., Krinock, R. A., Matsumura, T., Sussman, J. J., Fox, B. A., Chang, A. E., and Terman, D. S. Stimulation of tumor-draining lymph node cells with superantigenic staphyloeoccal toxins leads to the generation of tumor-specific effector T cells. J. Immunol., 152: 1277-1288, 1994.
20. Wexler, H. Accurate identification of experimental pulmonary metastases. J. Natl. Cancer Inst., 36: 641-645, 1966.
21. + tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res., 50: 2363-2370, 1990.
22. + tumor-draining lymph node cells involved in mediating tumor regression. J. Leukocyte Biol., 62: 507-516, 1997.
23. Goedegebuure, P. S., Zuber, M., Leonard-Vidal, D. L., Burger, U. L, Cusack, J. C., Chang, M. P., Douville, L. M., and Eberlein, T. J. Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. Surg. Oncol., 3: 79-89, 1994.
24. Earth, R. J., Mule, J. J., Spiess, P. J., and Rosenberg, S. A. Interferon γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8 + tumor-infiltrating lymphocytes. J. Exp. Med., 173: 647-658, 1991.
25. Aruga, A., Aruga, E., Tanigawa, K., Bishop, D. K., Sondak, V. K., and Chang, A. E. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol., in press, 1997.
26. Chang, A. E., Hyatt, C. L., and Rosenberg, S. A. Systemic administration of recombinant human interleukin-2 in mice. J. Biol. Response Modif., 3: 561-572, 1984.